Relay Therapeutics RLAY
NASDAQ RLAY
$18.97 -0.04 (-0.21%)
As of: Sep 4, 2026 · 1:35 PM EDT

Relay Therapeutics (RLAY) EBITDA Margin Growth (1y) (2022 - 2026)

Analysis

Relay Therapeutics (RLAY) EBITDA Margin Growth (1y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -143.00
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 78.00
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 1,135.00
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn 7,666.00
5 Revolution Medicines 44.05 Bn 44.05 Bn - -
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 1,238.00
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 2,002.00
8 Royalty Pharma 28.44 Bn 27.60 Bn - -1,651.00
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 29,091.00
10 Relay Therapeutics 3.85 Bn 3.85 Bn - -1.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.46 Mn
Mar 31, 2026 -151,446.00
Mar 31, 2025 -20,221.00
Mar 31, 2024 4.39 Mn
Dec 31, 2023 924.84 Mn
Sep 30, 2023 2.47 Mn
Jun 30, 2023 -6.78 Mn
Mar 31, 2023 -2.98 Mn
Dec 31, 2022 -1.69 Mn
Sep 30, 2022 -1.58 Mn
Jun 30, 2022 161,794.00
Mar 31, 2022 -1.05 Mn